RxDoctor Payments Data

Paul Johnson, MD

Interventional Cardiology · Athens, GANPI 1164682134

Payments from drug & device makers

$1,817in general payments, 2019–2025

Across 94 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$355
  • Amgen$260
  • Cardiva Medical, Inc.$253
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$230
  • Shockwave Medical, Inc$126
  • Edwards Lifesciences$85
  • plus $507 from 16 others

What the payments were for

  • Food & beverage$1,79999%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,817 in reported general payments places this provider in the 10th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$248,969
Medicare patients
1,809
Services billed
4,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab368$387,886
EliquisApixaban260$300,776
EntrestoSacubitril/Valsartan71$90,245
BrilintaTicagrelor72$63,072
Praluent PenAlirocumab57$53,706
JardianceEmpagliflozin36$40,746
XareltoRivaroxaban31$36,981
FarxigaDapagliflozin Propanediol24$26,795
Repatha SyringeEvolocumab12$13,414
Metoprolol Succinate595$6,352
VascepaIcosapent Ethyl13$5,904
Atorvastatin Calcium569$5,059
ClopidogrelClopidogrel Bisulfate373$4,743
Isosorbide Mononitrate ErIsosorbide Mononitrate280$3,701
Potassium Chloride180$2,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$300,776260 claims
NovartisEntresto$355$90,24571 claims
AstraZenecaBrilinta, Farxiga$17$89,86796 claims
Boehringer IngelheimJardiance$34$40,74636 claims
Johnson & JohnsonXarelto$62$36,98131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →